Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT00690482
Last Updated: 2014-01-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
118 participants
INTERVENTIONAL
2008-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00629239
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00703391
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00758459
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01205269
A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients
NCT01498081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD1981
AZD1981 Oral tablet, twice daily
AZD1981
Oral tablet, twice daily
Placebo
Placebo Oral tablet, twice daily
Placebo
Placebo Oral tablet, twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1981
Oral tablet, twice daily
Placebo
Placebo Oral tablet, twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of COPD
Exclusion Criteria
* Exacerbation of COPD within 30 days
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jörgen Vestbo
Role: PRINCIPAL_INVESTIGATOR
Professor in Respiratory Medicine, Hvidovre, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Pleven, , Bulgaria
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Arhus C, , Denmark
Research Site
Hellerup, , Denmark
Research Site
Hvidovre, , Denmark
Research Site
Værløse, , Denmark
Research Site
Krakow, , Poland
Research Site
Lublin, , Poland
Research Site
Ostrów Wielkopolski, , Poland
Research Site
Przemyśl, , Poland
Research Site
Rzeszów, , Poland
Research Site
Bojnice, , Slovakia
Research Site
Liptovský Hrádok, , Slovakia
Research Site
Poprad, , Slovakia
Research Site
Spišská Nová Ves, , Slovakia
Research Site
Žilina, , Slovakia
Research Site
Lund, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med. 2013 Nov;107(11):1722-30. doi: 10.1016/j.rmed.2013.06.006. Epub 2013 Jul 1.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9831C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.